论文部分内容阅读
目的 :观察评价善得定对重症急性胰腺炎 (SAP)的临床疗效。方法 :SAP 级 32例 ,SAP 级 2 9例 ,各随机分为普通治疗组 (N组 )和联用善得定组 (S组 ) ,观察比较两级 N、S两组临床疗效。结果 :两级 SAP患者 ,S组 Binder合并症积分下降较快 (P<0 .0 0 1) ,住院时间较短 (P<0 .0 1)。SAP 级 S组后遗症发生率较低 (P<0 .0 5 )。在 SAP 级 S组 ICU监护时间较短 (P<0 .0 5 ) ,转手术率较低 (P<0 .0 5 )。两级 S组均未发现与善得定确切相关的严重不良反应。结论 :SAP患者在综合救治的基础上早期使用善得定能显著改善临床症状过程 ,缩短疗程 ,改善预后 ,近期疗效确切。
Objective: To observe and evaluate the effect of Chandivenz on severe acute pancreatitis (SAP). Methods: 32 cases of SAP and 29 cases of SAP were randomly divided into general treatment group (N group) and combined treatment group (S group). Clinical efficacy of two levels of N and S groups were observed and compared. Results: In two SAP patients, the scores of Binder complications in S group decreased rapidly (P <0.01) and hospitalization time was shorter (P <0.01). SAP grade S group sequelae incidence was lower (P <0. 05). In the SAP class S ICU custody time is shorter (P <0. 05), lower rate of surgery (P <0. 05). No significant adverse reactions were found to be related to the exact scores of both groups. Conclusion: The early treatment of SAP patients based on the comprehensive treatment can significantly improve the clinical symptoms, shorten the course of treatment and improve the prognosis, the exact effect in the near future.